BACKGROUND Erlotinib is a standard first‐line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …

Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …

8074 Background: Erlotinib is an EGFR tyrosine kinase inhibitor (TKI) which is FDA-
approved at the maximum tolerated dose (MTD) of 150mg daily with dose limiting toxicities …

Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …

Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …

Background Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in non-
small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth …

8023 Background: The purpose of the study was to evaluate the efficacy of erlotinib and the
feasibility of screening for EGFR mutations in advanced NSCLC p (chemonaive or relapsed …

BACKGROUND: Targeting epidermal growth factor receptors (EGFR) is an innovative
approach to managing non-small cell lung cancer (NSCLC) which harbors EGFR mutation …

7503 Background: EGFR tyrosine kinase activating mutations are present in 10-26% of
NSCLC tumors and are associated with increased response to gefitinib and erlotinib …

Background We conducted a phase II trial of erlotinib in patients with advanced non-small-
cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and …